Referred to the House Committee on Energy and Commerce.
The bill directs the NIH to expand, intensify, and coordinate research on triple-negative breast cancer (TNBC), with coordination by the Office of Research on Women’s Health. It requires the CDC to develop and disseminate public education about TNBC, emphasizing elevated risk among minority women, and directs HRSA to provide informational outreach to health care providers.
Debate over unspecified funding: open-ended authorization versus fiscal limits
Relative to its intended legislative type, this bill clearly establishes new statutory programs by adding a PHSA section that directs NIH, CDC, and HRSA to undertake TNBC research, public education, and provider information activities and authorizes appropriations for FY2026–2031.
The bill directs the NIH to expand, intensify, and coordinate research on triple-negative breast cancer (TNBC), with coordination by the Office of Research on Women’s Health.
It requires the CDC to develop and disseminate public education about TNBC, emphasizing elevated risk among minority women, and directs HRSA to provide informational outreach to health care providers.
Each of the research, education, and provider-information provisions are authorized to receive “such sums as may be necessary” for fiscal years 2026–2031.
Content is narrow and noncontroversial so passage is plausible, but enactment depends on appropriations and legislative calendar.
Relative to its intended legislative type, this bill clearly establishes new statutory programs by adding a PHSA section that directs NIH, CDC, and HRSA to undertake TNBC research, public education, and provider information activities and authorizes appropriations for FY2026–2031. It defines the problem and assigns agency responsibilities, but provides only high-level directives and vague funding authorization without program design details, reporting requirements, or accountability measures.
Debate over unspecified funding: open-ended authorization versus fiscal limits
These are examples from the analysis, not a ranked list of the most-affected groups.
Debate over unspecified funding: open-ended authorization versus fiscal limits
Likely supportive because the bill targets a deadly, under-researched cancer and highlights racial disparities.
Sees federal research, public education, and provider outreach as appropriate tools to reduce inequities and improve early detection.
May want stronger, explicit funding amounts and equity-focused implementation.
Generally favorable as a targeted, evidence-oriented health initiative with bipartisan appeal.
Values the focus on research coordination and provider education, but will seek measurable goals, accountability, and fiscal clarity.
Wants clarity on overlap with existing programs and evaluation metrics.
Mildly supportive in principle because it funds medical research and provider information.
Concerned about open-ended spending authorizations and expanded federal programmatic roles in public education.
Prefers clearer fiscal constraints, private-sector involvement, and state-level implementation leeway.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and noncontroversial so passage is plausible, but enactment depends on appropriations and legislative calendar.
The bill has not accumulated any surfaced votes yet.
Debate over unspecified funding: open-ended authorization versus fiscal limits
Content is narrow and noncontroversial so passage is plausible, but enactment depends on appropriations and legislative calendar.
Relative to its intended legislative type, this bill clearly establishes new statutory programs by adding a PHSA section that directs NIH, CDC, and HRSA to undertake TNBC research, public education, and provider informa…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.